Executive Interviews

1. From Biggest Pharma To Rare Disease Start-Up 6/1/2023

   Martin Mackay’s journey from Pfizer executive to founding and leading a rare disease biotech is a reflection of the industry’s evolution from a small molecule powerhouse to multimodal biotech. 

2. Leading Aulos Bioscience’s “Triumvirate” Model 6/1/2023

   Aulos Bioscience hopes to leverage its unique business model, engineered by a VC firm and an Israeli biotech, to develop better treatments for solid tumors.

3. The Skin Is The Game: New Ways To Play In Dermatology 5/1/2023

   As the established indications in dermatology become saturated with competing products, a variety of companies, from start-ups to oncology players, are finding opportunities in underserved indications and reformulated drugs.

4. Fortress Biotech’s Network Flex Business Model 5/1/2023

   Fortress Biotech CEO Lindsay Rosenwald talks up Fortress Biotech’s business model, which leverages partner companies to develop promising but underexposed drug candidates.

5. Hitting The Ground Running In Oncology 4/3/2023

   David Lee, CEO at Servier Pharmaceuticals, talks about how he set up the French company’s U.S. division, and his goal of reaching $2 billion in annual oncology product revenue.

6. U.S. Patent Expired? Why Not Grow Revenue Globally, Says Amarin 4/3/2023

   Amarin is deploying a global strategy to expand patient access to Vascepa, hoping to make up for lost revenues in the U.S.

7. Gene Therapy Developer Rocket Pharma Aims High 3/1/2023

   “From our first patient until now, all our manufactured drug product that has treated patients has been produced in partnership with CDMOs,” says Gaurav Shah, M.D., cofounder and CEO of Rocket Pharma.

8. Translating Nobel Prize Winning Science Into Medicine 3/1/2023

   2022 Nobel Prize winner Carolyn Bertozzi discusses her approach to translating scientific discoveries into biopharmaceutical products, and her ongoing partnership with Shasqi CEO José Mejía Oneto.

9. Making The Right Deal For Biohaven 3/1/2023

   Biohaven CEO Vlad Coric describes the events leading up to Pfizer’s $11.6 billion acquisition, his drug launch during the start of COVID-19, and why company titles and seniority don’t really matter.

10. Why Takeda Is Focusing So Much On Plasma-Derived Therapies 2/1/2023

    Tasked with driving future growth of Takeda’s plasma-derived therapies, Giles Platford, business unit president, shares his approach to partnering, promoting market access, and improving patient experiences.